A report by…[Oxfam International] has criticized the world’s top drug makers for their unwillingness to practice tiered pricing and discover drugs targeting so-called poor man’s diseases…and insistence on intellectual property rights at the cost of making drugs accessible to the people who need them most…The report categorizes all 12 drug makers as “defensive” in terms of their attitude towards patents…Ranga Iyer, the…head of the multinational drug makers lobby…[in India]… said that companies alone could not solve the problem and that all stakeholders, including the government, needed to play a role…[refers to Novartis, Wyeth]